ArticleEuropean heart journal2014
Association of cyclooxygenase-2 genetic variant with cardiovascular disease.
Article in European heart journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors.Scientific reports · 2017Pooled it
- Article
- Senescence-related epicardial adipocyte genes lead to immune infiltration and myocardial infarction progression.Frontiers in cardiovascular medicine · 2026Article
- Unveiling the molecular impact of pulmonary embolism on the right ventricle: a multi-layer transcriptomic study in a porcine model.Molecular and cellular biochemistry · 2026Article
- Exploring COX-Independent Pathways: A Novel Approach for Meloxicam and Other NSAIDs in Cancer and Cardiovascular Disease Treatment.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Prostanoids in Cardiac and Vascular Remodeling.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Article
- Article
- The Link between Prostanoids and Cardiovascular Diseases.International journal of molecular sciences · 2023Review
- Identification of Ferroptosis-Related Genes in Heart Failure Induced by Transverse Aortic Constriction.Journal of inflammation research · 2023Article
- Ferroptosis and Autophagy-Related Genes in the Pathogenesis of Ischemic Cardiomyopathy.Frontiers in cardiovascular medicine · 2022Article
- Atorvastatin attenuates ferroptosis-dependent myocardial injury and inflammation following coronary microembolizationFrontiers in pharmacology · 2022Article
- Effects of selenium intake on the expression of prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2) and matrix metallopeptidase-9 genes in the coronary artery disease: Selenegene study, a double-blind randomized controlled trial.ARYA atherosclerosis · 2021Article
- Tanyu Tongzhi Formula Delays Atherosclerotic Plaque Progression by Promoting Alternative Macrophage ActivationFrontiers in pharmacology · 2021Article
- Network Pharmacology and Molecular Docking-Based Analysis on Bioactive Anticoronary Heart Disease Compounds inEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Itaconate prevents abdominal aortic aneurysm formation through inhibiting inflammation via activation of Nrf2.EBioMedicine · 2020Article
- Article
- Regulatory T cells suppress the expression of COX-2 in vulnerable plaque.Heart and vessels · 2020Article
- Identification of Differentially Expressed Genes and Signaling Pathways in Acute Myocardial Infarction Based on Integrated Bioinformatics Analysis.Cardiovascular therapeutics · 2019Article
- MicroRNA-381 regulates the occurrence and immune responses of coronary atherosclerosis via cyclooxygenase-2.Experimental and therapeutic medicine · 2018Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 6 institutions in 3 countries.
Funding
Abstract
aimA genetic variant (rs20417) of the PTGS2 gene, encoding for COX-2, has been associated with decreased COX-2 activity and a decreased risk of cardiovascular disease (CVD). However, this genetic association and the role of COX-2 in CVD remain controversial. METHODS AND
resultsThe association of rs20417 with CVD was prospectively explored in 49 232 subjects (ACTIVE-A, CURE, epiDREAM/DREAM, ONTARGET, RE-LY, and WGHS) and the effect of potentially modifiable risk factors on the genetic association was further explored in 9363 INTERHEART participants. The effect of rs20417 on urinary thromboxane and prostacyclin metabolite concentrations was measured in 117 healthy individuals. Carriage of the rs20417 minor allele was associated with a decreased risk of major CVD outcomes (OR = 0.78, 95% CI: 0.70-0.87; P = 1.2 × 10(-5)). The genetic effect was significantly stronger in aspirin users (OR: 0.74, 95% CI: 0.64-0.84; P = 1.20 × 10(-5)) than non-users (OR: 0.87, 95% CI: 0.72-1.06; P = 0.16) (interaction P-value: 0.0041). Among patients with previous coronary artery disease (CAD), rs20417 carriers had a stronger protective effect on risk of major adverse events when compared with individuals without previous CAD (interaction P-value: 0.015). Carriers had significantly lower urinary levels of thromboxane (P = 0.01) and prostacyclin (P = 0.01) metabolites when compared with non-carriers.
conclusionThe rs20417 polymorphism is associated with a reduced risk of major cardiovascular events and lower levels of thromboxane and prostacyclin. Our results suggest that a genetic decrease in COX-2 activity may be beneficial with respect to CVD risk, especially, in higher risk patients on aspirin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.